

---

## THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

---

**If you are in any doubt** as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker, a licensed securities dealer or other registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

**If you have sold or transferred** all your shares in Vincent Medical Holdings Limited (永勝醫療控股有限公司), you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker, licensed securities dealer, registered institution in securities or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this circular.

---



**PROPOSALS FOR**  
**(1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES;**  
**AND**  
**(2) RE-ELECTION OF RETIRING DIRECTORS**  
**AND**  
**NOTICE OF ANNUAL GENERAL MEETING**

---

A notice convening the annual general meeting (the “AGM”) of Vincent Medical Holdings Limited (the “Company”) to be held at 17th Floor, Leighton, 77 Leighton Road, Causeway Bay, Hong Kong on Thursday, 18 May 2023 at 10:00 a.m. is set out on pages 17 to 21 of this circular. A form of proxy for use at the AGM is also enclosed. Whether or not you are able to attend the AGM, please complete and sign the form of proxy in accordance with the instructions printed thereon and return it to the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the AGM (or at any adjournment). **Completion and return of the form of proxy will not preclude shareholders of the Company from attending and voting in person at the AGM (or at any adjournment) if you so wish and in such event, the form of proxy previously submitted shall be deemed to be revoked.**

In the event of any inconsistency, the English version of this circular shall prevail over the Chinese version.

---

## CONTENTS

---

	<i>Page</i>
<b>DEFINITIONS</b> .....	1
 <b>LETTER FROM THE BOARD</b>	
1. <b>INTRODUCTION</b> .....	4
2. <b>GENERAL MANDATES TO ISSUE SHARES           AND REPURCHASE SHARES</b> .....	5
3. <b>RE-ELECTION OF RETIRING DIRECTORS</b> .....	6
4. <b>AGM AND PROXY ARRANGEMENT</b> .....	7
5. <b>RESPONSIBILITY STATEMENT</b> .....	8
6. <b>RECOMMENDATION</b> .....	8
7. <b>GENERAL INFORMATION</b> .....	8
 <b>APPENDIX I – EXPLANATORY STATEMENT ON THE                   REPURCHASE MANDATE</b> .....	
	9
 <b>APPENDIX II – DETAILS OF THE DIRECTORS PROPOSED                   TO BE RE-ELECTED AT THE AGM</b> .....	
	13
 <b>NOTICE OF AGM</b> .....	17

---

## DEFINITIONS

---

*In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:*

“AGM”	the annual general meeting of the Company to be held at 17th Floor, Leighton, 77 Leighton Road, Causeway Bay, Hong Kong on Thursday, 18 May 2023 at 10:00 a.m. or any adjournment thereof, the notice of which is set out on pages 17 to 21 of this circular
“Articles of Association”	the articles of association of the Company currently in force
“Board”	the board of the Directors
“Board Diversity Policy”	the board diversity policy of the Company as amended from time to time
“Cayman Companies Act”	the Companies Act, Cap. 22 (Act 3 of 1961, as consolidated and revised) of the Cayman Islands
“close associate”	has the meaning ascribed to it under the Listing Rules
“Company”	Vincent Medical Holdings Limited (永勝醫療控股有限公司), an exempted company incorporated in the Cayman Islands with limited liability whose shares are listed on the Main Board of the Stock Exchange (stock code: 1612)
“Controlling Shareholder(s)”	Mr. Choi Man Shing, Ms. Liu Pui Ching (the spouse of Mr. Choi Man Shing), VRI and VRHK, being the controlling shareholders who jointly control their respective interests in the Company within the meaning of the Listing Rules
“core connected person”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	Hong Kong Special Administrative Region of the PRC
“Issuing Mandate”	a general and unconditional mandate to be granted to the Directors to allot, issue and deal with additional Shares during the relevant period of an aggregate number not exceeding 20% of the total number of issued Shares of the Company as at the date of passing of the relevant resolution granting such mandate

---

## DEFINITIONS

---

“Latest Practicable Date”	18 April 2023, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information contained herein
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Nomination Committee”	the nomination committee of the Board
“PRC”	the People’s Republic of China
“Remuneration Committee”	the remuneration committee of the Board
“Repurchase Mandate”	a general and unconditional mandate to be granted to the Directors to repurchase Shares on the Stock Exchange up to a maximum number equivalent to 10% of the total number of issued Shares of the Company as at the date of passing the relevant resolution granting such mandate
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Share(s)”	ordinary share(s) of par value of HK\$0.01 each in the share capital of the Company, or if there has been a sub-division, consolidation, reclassification or reconstruction or reduction or reorganisation of the share capital of the Company, shares forming part of the ordinary equity share capital of the Company as shall result from any of such sub-division, consolidation, re-classification or re-construction or reduction or reorganisation
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Takeovers Code”	the Code on Takeovers and Mergers issued by the Securities and Futures Commission of Hong Kong, as amended, supplemented or otherwise modified from time to time
“VRHK”	VINCENT RAYA CO., LIMITED (永勝宏基集團有限公司), a company incorporated in Hong Kong and a direct wholly-owned subsidiary of VRI as at the Latest Practicable Date, and one of the Controlling Shareholders

---

## DEFINITIONS

---

“VRI” VINCENT RAYA INTERNATIONAL LIMITED, a company incorporated in the British Virgin Islands and being held as to 57.89% by Mr. Choi Man Shing (being the Chairman and executive Director) and 42.11% by Ms. Liu Pui Ching (being the spouse of Mr. Choi Man Shing) as at the Latest Practicable Date, and one of the Controlling Shareholders

“%” per cent.

---

LETTER FROM THE BOARD

---



**Vincent  
Medical**

**Vincent Medical Holdings Limited**

**永勝醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 1612)

**Executive Directors:**

Mr. CHOI Man Shing (*Chairman*)  
Mr. CHOI Cheung Tai Raymond (*Chief Executive Officer*)  
Mr. KOH Ming Fai  
Mr. FU Kwok Fu

**Non-executive Director:**

Mr. GUO Pengcheng

**Independent Non-executive Directors:**

Mr. MOK Kwok Cheung Rupert  
Mr. AU Yu Chiu Steven  
Prof. YUNG Kai Leung

**Registered Office:**

Cricket Square  
Hutchins Drive  
P.O. Box 2681  
Grand Cayman, KY1-1111  
Cayman Islands

**Headquarters and Principal**

**Place of Business in Hong Kong:**

Units 1604-07A, 16/F.  
Two Harbourfront  
22 Tak Fung Street  
Hung Hom, Kowloon  
Hong Kong

21 April 2023

*To the Shareholders*

Dear Sir or Madam,

**PROPOSALS FOR**

**(1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES;**

**AND**

**(2) RE-ELECTION OF RETIRING DIRECTORS**

**1. INTRODUCTION**

The purpose of this circular is to give you the notice of the AGM and the information in respect of the ordinary resolutions to be proposed at the AGM for, inter alia, (i) the grant to the Directors the Issuing Mandate and the Repurchase Mandate; (ii) the extension of the Issuing Mandate to include Shares repurchased pursuant to the Repurchase Mandate; and (iii) the re-election of the retiring Directors.

---

## LETTER FROM THE BOARD

---

### 2. GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES

At the annual general meeting of the Company held on 24 May 2022, resolutions were passed giving general and unconditional mandates to the Directors (i) to allot, issue and deal with Shares not exceeding 20% of the aggregate total number of issued Shares of the Company; (ii) to repurchase Shares not exceeding 10% of the aggregate total number of issued Shares of the Company; and (iii) to extend the general mandate of (i) above to include Shares repurchased pursuant to the general mandate of (ii) above. Such general mandates will expire at the conclusion of the forthcoming AGM.

At the AGM, separate ordinary resolutions will be proposed:

- (a) to grant the Issuing Mandate to the Directors to exercise the powers of the Company to allot, issue, and deal with any Shares not exceeding 20% of the total number of issued Shares of the Company as at the date of passing of the resolution. The Issuing Mandate will end on the earliest of (i) the date of the next annual general meeting; (ii) the date by which the next annual general meeting of the Company is required to be held by the Articles of Association or any applicable laws of the Cayman Islands; and (iii) the date upon which such authority is revoked, varied or renewed by an ordinary resolution of the Shareholders at a general meeting of the Company. Based on the 653,336,332 Shares in issue as at the Latest Practicable Date and assuming no further Shares will be issued or repurchased during the period from the Latest Practicable Date to the date of the AGM, the Directors will be authorised to issue up to 130,667,266 Shares under the Issuing Mandate;
- (b) to grant the Repurchase Mandate to the Directors to exercise the powers of the Company to repurchase issued Shares subject to the criteria set out in this circular. Under such Repurchase Mandate, the maximum number of Shares that the Directors may repurchase shall not exceed 10% of the total number of issued Shares of the Company as at the date of passing of the resolution. As at the Latest Practicable Date, the number of Shares in issue was 653,336,332 Shares. Subject to the passing of the proposed ordinary resolution approving the grant of the Repurchase Mandate and assuming no further Shares will be issued or repurchased during the period from the Latest Practicable Date to the date of the AGM, the Company would be allowed under the Repurchase Mandate to repurchase a maximum of 65,333,633 Shares, being 10% of the total number of issued Shares of the Company as at the date of passing of the resolution in relation thereto. The Repurchase Mandate will end on the earliest of (i) the date of the next annual general meeting; (ii) the date by which the next annual general meeting of the Company is required to be held by the Articles of Association or any applicable laws of the Cayman Islands; and (iii) the date upon which such authority is revoked, varied or renewed by an ordinary resolution of the Shareholders at a general meeting of the Company; and
- (c) subject to the passing of the aforesaid ordinary resolutions granting the Issuing Mandate and the Repurchase Mandate, to extend the number of Shares to be issued and allotted under the Issuing Mandate by an additional number representing such number of Shares repurchased under the Repurchase Mandate.

---

## LETTER FROM THE BOARD

---

Pursuant to the Listing Rules, an explanatory statement is set out in Appendix I to this circular to provide you with requisite information reasonably necessary to enable you to make an informed decision on whether to vote for or against the proposed resolution granting the Repurchase Mandate at the AGM.

### 3. RE-ELECTION OF RETIRING DIRECTORS

As at the Latest Practicable Date, there were four executive Directors, namely Mr. Choi Man Shing, Mr. Choi Cheung Tai Raymond, Mr. Koh Ming Fai and Mr. Fu Kwok Fu; one non-executive Director, namely Mr. Guo Pengcheng; and three independent non-executive Directors, namely Mr. Mok Kwok Cheung Rupert, Mr. Au Yu Chiu Steven and Prof. Yung Kai Leung.

In accordance with Articles 84(1) and (2) of the Articles of Association, Mr. Choi Man Shing, Mr. Guo Pengcheng and Prof. Yung Kai Leung shall retire from office by rotation and be eligible for re-election at the AGM. Mr. Choi Man Shing and Prof. Yung Kai Leung will offer themselves for re-election at the AGM. Mr. Guo Pengcheng confirmed that due to his intention to focus on other business engagements and personal commitments, he will not offer himself for re-election as a non-executive Director and will retire from the Board with effect from the conclusion of the AGM.

Also, pursuant to Article 83(3) of the Articles of Association, Mr. Choi Cheung Tai Raymond, being the new Director so appointed by the Board as an executive Director to fill a casual vacancy on the Board as disclosed in the announcement of the Company dated 30 December 2022, shall hold office until the AGM and shall then be eligible, will offer himself for re-election at the AGM.

Recommendations to the Board for the proposal for re-election of each of Mr. Choi Man Shing and Mr. Choi Cheung Tai Raymond as an executive Director, and Prof. Yung Kai Leung as an independent non-executive Director were made by the Nomination Committee, after having considered a range of diversity perspectives including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service, as set out in the Board Diversity Policy.

At the AGM, separate ordinary resolutions will be put forward to the Shareholders in relation to the proposed re-election of each of Mr. Choi Man Shing and Mr. Choi Cheung Tai Raymond as an executive Director, and Prof. Yung Kai Leung as an independent non-executive Director. The biographical details of the above-named Directors who are subject to re-election at the AGM are set out in Appendix II to this circular in compliance with the relevant requirements of the Listing Rules.



---

## LETTER FROM THE BOARD

---

### **Recommendation of the Nomination Committee with respect to the independent non-executive Director subject to re-election at the AGM**

All independent non-executive Directors have made an annual confirmation of independence pursuant to Rule 3.13 of the Listing Rules, respectively. The Nomination Committee had assessed and reviewed the written confirmation of independence of Prof. Yung Kai Leung who has offered himself for re-election as an independent non-executive Director at the AGM based on the independence criteria as set out in Rule 3.13 of the Listing Rules and is satisfied that he remains independent in accordance with Rule 3.13 of the Listing Rules. In addition, the Nomination Committee had evaluated his performance and is of the view that he has provided valuable contributions to the Company and has demonstrated his abilities to provide independent, balanced and objective view to the Company's affairs.

Based on the Board Diversity Policy, the Nomination Committee considers that Prof. Yung Kai Leung can contribute to the diversity of the Board, in particular, with his strong and diversified educational background, skills and professional experience in his expertise.

Therefore, the Board, with the recommendation of the Nomination Committee, has nominated Prof. Yung Kai Leung for re-election as an independent non-executive Director at the AGM.

#### **4. AGM AND PROXY ARRANGEMENT**

Set out on pages 17 to 21 of this circular is the notice of AGM at which ordinary resolutions will be proposed to the Shareholders to consider and approve, among other matters, (i) the grant to the Directors the Issuing Mandate and the Repurchase Mandate; (ii) the extension of the Issuing Mandate to include Shares repurchased pursuant to the Repurchase Mandate; and (iii) the re-election of the retiring Directors.

A form of proxy for use at the AGM is enclosed with this circular. Such form of proxy is also published on the designated website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the website of the Company ([www.vincentmedical.com](http://www.vincentmedical.com)). Whether or not you intend to be present at the AGM, you are requested to complete the form of proxy and return it in accordance with the instructions printed thereon to the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the AGM (or at any adjournment). Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the AGM (or any adjournment) if you so wish and in such event, the form of proxy previously submitted shall be deemed to be revoked.

---

## LETTER FROM THE BOARD

---

All resolutions will be put to vote by way of poll at the AGM pursuant to Rule 13.39 of the Listing Rules. An announcement on the poll results will be made by the Company after the AGM in the manner prescribed under Rule 13.39(5) of the Listing Rules.

To the best of the Directors' knowledge, information and belief having made reasonable enquiries, the Directors confirm that no Shareholder is required to abstain from voting on any resolutions at the AGM.

### 5. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make this circular or any statement herein misleading.

### 6. RECOMMENDATION

The Directors consider that (i) the granting of the Issuing Mandate and the Repurchase Mandate to the Directors to issue and repurchase Shares; (ii) the extension of the Issuing Mandate to include Shares repurchased pursuant to the Repurchase Mandate; and (iii) the re-election of the retiring Directors are in the best interests of the Company and the Shareholders as a whole. The Directors therefore recommend the Shareholders to vote in favour of all the resolutions to be proposed at the AGM.

### 7. GENERAL INFORMATION

Your attention is drawn to the additional information set out in the appendices to this circular.

Yours faithfully  
By order of the Board  
**Vincent Medical Holdings Limited**  
**Choi Man Shing**  
*Chairman and Executive Director*

*This is an explanatory statement given to all Shareholders relating to a resolution to be proposed at the AGM for approving the Repurchase Mandate. The explanatory statement which contains all the information required pursuant to Rule 10.06(1)(b) of the Listing Rules and other relevant provisions of the Listing Rules is set out as follows:*

### **1. LISTING RULES RELATING TO THE SHARE REPURCHASE**

The Listing Rules permit companies whose primary listings are on the Stock Exchange to repurchase their securities on the Stock Exchange subject to certain restrictions. Among such restrictions, the Listing Rules provide that the shares of such company must be fully paid up and all share repurchases by such company must be approved in advance by an ordinary resolution of shareholders, either by way of a general mandate or by specific approval of a particular transaction.

### **2. SHARE CAPITAL**

As at the Latest Practicable Date, the total number of issued Shares were 653,336,332. Subject to the passing of the resolution granting the Repurchase Mandate and on the basis that no further Shares are issued or repurchased during the period from the Latest Practicable Date to the date of the AGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 65,333,633 Shares, being 10% of the total number of issued Shares of the Company as at the date of the passing of the relevant resolution at the AGM.

### **3. REASONS FOR SHARE REPURCHASE**

The Directors have no present intention to repurchase any Shares but consider that the ability to do so would give the Company the flexibility that would be beneficial to the Company and the Shareholders as such repurchase may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value and/or earnings per Share of the Company and will only be made when the Directors believe that such a repurchase will benefit the Company and the Shareholders as a whole.

As compared with the financial position of the Company as at 31 December 2021 (being the date to which the latest published audited consolidated accounts of the Company have been made), the Directors consider that there might be a material adverse impact on the working capital and on the gearing position of the Company in the event that the proposed repurchases were to be carried out in full during the proposed repurchase period. However, the Directors do not intend to exercise the Repurchase Mandate to such an extent which would, in the circumstances, have a material adverse impact on the working capital or gearing position of the Company.

**4. FUNDING OF SHARE REPURCHASE**

The Company is empowered by its memorandum of association and the Articles of Association to repurchase its Shares. In repurchasing Shares, the Company may only apply funds legally available for such purpose in accordance with its memorandum of association and the Articles of Association, the Listing Rules, the applicable laws of the Cayman Islands and/or any other applicable laws, as the case may be.

Under the Listing Rules, a listed company is prohibited from repurchasing its own securities on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time.

The laws of the Cayman Islands provide that payment for a share repurchase may only be made out of the profits, the share premium account or the proceeds of a new issue of Shares made for such purpose or, subject to the Cayman Companies Act, out of capital of the Company. The amount of premium over the par value of the Shares payable on the repurchase of Shares may only be paid out of either or both of the profits or the share premium account of the Company or, subject to the Cayman Companies Act, out of capital of the Company.

In addition, under the laws of the Cayman Islands, payment out of capital by a company for the repurchase by a company of its own shares is unlawful unless immediately following the date on which the payment is proposed to be made, the Company shall be able to pay its debts as they fall due in the ordinary course of business. In accordance with the laws of the Cayman Islands, the shares so repurchased would be treated as cancelled but the total number of authorised shares to be issued would not be reduced.

**5. DIRECTORS AND THEIR CLOSE ASSOCIATES, AND THE COMPANY'S CORE CONNECTED PERSONS**

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their close associates, has any present intention to sell any Shares to the Company in the event that the Repurchase Mandate is granted by the Shareholders.

No core connected person of the Company has notified the Company that he/she/it has a present intention to sell Shares to the Company nor has he/she/it undertaken not to sell any of the Shares held by him/her/it to the Company in the event that the Repurchase Mandate is granted by the Shareholders.

**6. UNDERTAKING OF THE DIRECTORS**

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the powers of the Company to make share repurchases pursuant to the Repurchase Mandate and in accordance with the Listing Rules, the Articles of Association and the laws of the Cayman Islands.

**7. EFFECT OF THE TAKEOVERS CODE AND MINIMUM PUBLIC HOLDING**

A repurchase of Shares by the Company may result in an increase in the proportionate interests of a Shareholder in the voting rights of the Company, which may give rise to an obligation on certain Shareholder or a group of Shareholders acting in concert (as defined in the Takeovers Code) to make a mandatory offer in accordance with Rule 26 of the Takeovers Code for all the Shares not already owned by such Shareholder or group of Shareholders.

As at the Latest Practicable Date, to the best of the knowledge and belief of the Directors, the Controlling Shareholders, consisting of Mr. Choi Man Shing (our Chairman and executive Director), Ms. Liu Pui Ching (the spouse of Mr. Choi Man Shing), VRI and VRHK, were interested in a total of 391,189,890 Shares, representing approximately 59.88% of the issued share capital of the Company.

In the opinion of the Directors, on the basis of the current aggregate shareholding of the Controlling Shareholders, an exercise of the Repurchase Mandate in full will not result in the Controlling Shareholders becoming obliged to make a mandatory offer under Rule 26 of the Takeovers Code.

Save as disclosed above, the Directors are not aware of any Shareholder or group of Shareholders acting in concert (as defined in the Takeovers Code) who may become obliged to make a mandatory offer under Rule 26 of the Takeovers Code as a consequence of any repurchase of Shares pursuant to the Repurchase Mandate.

The Directors have no intention to exercise the Repurchase Mandate to such an extent that it would result in the number of Shares held by the public being reduced to less than 25% (or such other prescribed minimum percentage as determined by the Stock Exchange) of the issued share capital of the Company.

**8. SHARE REPURCHASE BY THE COMPANY**

The Company had not repurchased any Shares (whether on the Stock Exchange or otherwise) in the six months preceding the Latest Practicable Date.

**9. SHARE PRICES**

During each of the previous twelve months up to and including the Latest Practicable Date, the highest and lowest trading prices during each month for the Shares on the Stock Exchange were as follows:

<b>Month</b>	<b>Highest HK\$</b>	<b>Lowest HK\$</b>
<b>2022</b>		
April	0.910	0.740
May	0.780	0.680
June	0.750	0.660
July	0.720	0.620
August	0.670	0.470
September	0.485	0.375
October	0.420	0.380
November	0.810	0.400
December	0.730	0.550
<b>2023</b>		
January	0.700	0.570
February	0.600	0.460
March	0.465	0.400
April (up to and including the Latest Practicable Date)	0.450	0.400

*Source: the website of the Stock Exchange*

*The biographical details of the Directors (as required by the Listing Rules) proposed to be re-elected at the AGM are set out below:*

### EXECUTIVE DIRECTORS

**Mr. CHOI Man Shing (蔡文成) (“Mr. Choi”)**, aged 70, is the chairman and an executive Director of the Company, the chairman of the Nomination Committee and a member of the Remuneration Committee. He currently serves as a director of many subsidiaries of the Company. Mr. Choi is the founder of the Group and primarily responsible for formulating long-term development and marketing strategies of the Group. He has over 44 years of management experience in the manufacturing industry in Hong Kong and the PRC. Mr. Choi is (i) the father of Mr. Choi Cheung Tai Raymond, an executive Director and the chief executive officer of the Company; (ii) the spouse of Ms. Liu Pui Ching, the Controlling Shareholder; and (iii) a director of VRI (a Controlling Shareholder) and certain of its subsidiaries.

Mr. Choi has entered into a service agreement with the Company for an initial fixed term of three years commencing from 24 June 2016. The service agreement may be terminated in accordance with the respective terms of the service agreement. Mr. Choi is entitled to receive a service fee of HK\$1.00 as an executive Director per annum and the total remuneration of Mr. Choi for the year ended 31 December 2022 was approximately HK\$1,448,000.

As at the Latest Practicable Date, Mr. Choi is interested in an aggregate of 391,189,890 Shares, representing approximately 59.88% of the issued share capital of the Company, within the meaning of Part XV of the SFO. Also, Mr. Choi is interested in an aggregate of 4,750 shares of VRI (a holding company of the Company and hence an associated corporation of the Company under Part XV of the SFO), representing 100% of the issued share capital of VRI, within the meaning of Part XV of the SFO. As at the Latest Practicable Date, save as otherwise disclosed herein, Mr. Choi is not interested in any other securities issued by the Company or any of its associated corporations within the meaning of Part XV of the SFO.

Mr. Choi was the person-in-charge of VINCENT RAYA (DONGGUAN) ELECTRONICS CO., LTD Wuhan Sales Office\* (永勝(東莞)電子有限公司武漢經營部) (“**Wuhan Sales Office**”), an unincorporated business entity established in the PRC, when its business licence was revoked. As Mr. Choi was in the process of winding down the business of Wuhan Sales Office with a view to dissolution of such office, Wuhan Sales Office did not attend to annual examination and its business licence was subsequently revoked on 25 December 2003.

Mr. Choi was also the person-in-charge of VINCENT RAYA (DONGGUAN) ELECTRONICS CO., LTD. Tianjin Sales Office\* (永勝(東莞)電子有限公司天津經營部) (“**Tianjin Sales Office**”), an unincorporated business entity established in the PRC, when its business licence was revoked. As Mr. Choi was in the process of winding down the business of Tianjin Sales Office with a view to dissolution of such office, Tianjin Sales Office did not attend to annual examination and its business licence was subsequently revoked on 31 December 2008.

Mr. Choi was also the legal representative of Wuhan Vincent Electric Engineering Company Limited\* (武漢永勝機電工程有限公司) (“**Wuhan Vincent Electric**”), a wholly foreign-owned enterprise established in the PRC which manufactured and sold electrical components, electrical and electronic products and various types of sensors before its business licence was revoked. Mr. Choi had voluntarily commenced the dissolution process of Wuhan Vincent Electric. As Wuhan Vincent Electric was in the process of being dissolved, it did not attend to annual examination and its business licence was subsequently revoked on 25 April 2001 (the “**Revocation Incident**”, together with the revocation of the business licences of Wuhan Sales Office and Tianjin Sales Office, the “**Relevant Incidents**”).

According to Article 146 of the PRC Company Law\* (《中華人民共和國公司法》), a legal representative of a company or enterprise whose (i) business licence has been revoked; and (ii) is personally liable for such revocation, should not be appointed as a director, supervisor or member of senior management of a company or enterprise in the PRC for a period of three years from the date of revocation of the business licence (the “**Three-year Prohibition**”). As disclosed in the Company’s prospectus dated 30 June 2016 (the “**Prospectus**”), Zhong Lun Law Firm (the legal advisers of the Company as to PRC law for the listing application of the Company, the “**PRC Legal Advisers**”) advised that, Wuhan Sales Office and Tianjin Sales Office are unincorporated business entities that are not qualified as legal persons and therefore do not fall within the ambit of Article 146 of the PRC Company Law\* (《中華人民共和國公司法》). Hence, Mr. Choi is not subject to the Three-year Prohibition in respect of his acting as the person-in-charge of Wuhan Sales Office and Tianjin Sales Office. The PRC Legal Advisers confirmed that such revocations had not affected the appointment of Mr. Choi as the legal representative(s) and/or director(s) of the Group’s PRC subsidiaries.

During the Three-year Prohibition, Mr. Choi was appointed as the legal representative and chairman of Vincent Medical (Dongguan) Mfg. Co. Ltd. (東莞永勝醫療製品有限公司) (“**VMDG**”), an indirect non-wholly owned subsidiary of the Company (“**Appointments**”). As disclosed in the Prospectus, the PRC Legal Advisers confirmed, having reviewed all the documents retrieved from the Wuhan Administration for Industry & Commerce, that they have found no record that indicates Mr. Choi is personally liable for the Revocation Incident. Mr. Choi also confirmed that he bears no personal liability for the Revocation Incident. Further, the Appointments were registered and confirmed by the Dongguan Administration for Industry & Commerce, and VMDG has confirmed that it has not been subject to any penalty or investigation as a result of the Appointments. Therefore, the PRC Legal Advisers were of the opinion that the Revocation Incident would not result in any material legal impediment to Mr. Choi’s appointments as director(s) and/or legal representative(s) of the Group’s PRC subsidiaries.

Mr. Choi confirmed that, save for the Three-year Prohibition and as disclosed above, the Relevant Incidents did not result in any restriction, responsibility or penalty imposed against him. Since (i) the Relevant Incidents were a result of the failure of Wuhan Sales Office, Tianjin Sales Office and Wuhan Vincent Electric to attend annual examination within the specific time period during the winding down or dissolution process; (ii) Mr. Choi did not hold positions of legal representative, director, supervisor or member of senior management in any other PRC companies whose business licence has been revoked; (iii) the Three-year Prohibition period has lapsed; (iv) there has been no recurrence of similar incidents since 1 January 2009; and (v) the Relevant Incidents did not involve any dishonesty on the part of Mr. Choi nor impugn on his integrity or competence, the Board is of the view that the suitability of Mr. Choi to act as a director of a listed issuer under Rules 3.08 and 3.09 of the Listing Rules is not affected by the Relevant Incidents.



**Mr. Choi Cheung Tai Raymond (蔡章泰)** (“**Mr. Raymond Choi**”), aged 41, is an executive Director and chief executive officer of the Company. He also currently serves as a director of various subsidiaries of the Company. Mr. Raymond Choi joined the Group in May 2020 and is primarily responsible for overseeing the corporate management of the Group, formulating our business and product development strategies. Mr. Raymond Choi is (i) the son of Mr. Choi Man Shing, an executive Director, chairman of the Board and the Controlling Shareholder; (ii) the son of Ms. Liu Pui Ching, the spouse of Mr. Choi Man Shing and the Controlling Shareholder; and (iii) a director of VRI (a Controlling Shareholder) and certain of its subsidiaries.

Mr. Raymond Choi obtained a degree of bachelor of science majoring in industrial engineering from The Pennsylvania State University, the United States in May 2005 and a degree in master of business administration through distance learning from The University of Manchester, the United Kingdom in June 2014. Mr. Raymond Choi is a corporate member of The Hong Kong Institution of Engineers and a Professional Engineer (Manufacturing, Industrial and Systems) registered with the Engineers Registration Board, a body corporate established under the Engineers Registration Ordinance (Chapter 409 of the Laws of Hong Kong). He is a Registered Lean Sigma Black Belt of the Six Sigma Institute and a Certified Six Sigma Black Belt of the China Association for Quality. He is an Executive Board Member, a member of each of the Quality and Regulatory Affairs Panel and the Greater Bay Area Panel of the Hong Kong Medical and Healthcare Device Industries Association. He is also a member of Expert Review Panel of Logistics and Supply Chain MultiTech R&D Centre Limited. He has also been appointed as an industrial advisor of the Technology Transfer Management Committee of The Hong Kong Polytechnic University with effect from 1 April 2023.

Mr. Raymond Choi has over 17 years of experience in industrial engineering and operations management across medical device, cosmetics and beauty products and industrial and semiconductor system. Throughout his career he has worked for companies including MEDRAD, Inc. (subsequently acquired by Bayer AG), Sanmina-SCI Enclosure Systems (Asia) Ltd., VRHK, Dongguan Zensee Printing Limited (a subsidiary of Q P Group Holdings Limited (stock code: 1412.HK)) and Elegance Industrial Co., Ltd. (a subsidiary of Crystal International Group Limited (stock code: 2232.HK)).

Mr. Raymond Choi has entered into a service agreement with the Company for an initial fixed term of three years commencing from 1 January 2023. The service agreement may be terminated in accordance with the respective terms of the service agreement. Mr. Raymond Choi is entitled to receive a service fee of HK\$1.00 as an executive Director per annum and the total remuneration of Mr. Raymond Choi for the year ended 31 December 2022 was approximately HK\$1,365,000.

As at the Latest Practicable Date, Mr. Raymond Choi is interested in 9,200,000 Shares of the Company, representing 1.41% of the total issued share capital of the Company, and is also interested in a total of 2,000,000 share options granted under the share option scheme of the Company. As at the Latest Practicable Date, save as otherwise disclosed herein, Mr. Raymond Choi is not interested in any other securities issued by the Company or any of its associated corporations within the meaning of Part XV of the SFO.

**INDEPENDENT NON-EXECUTIVE DIRECTOR**

**Prof. YUNG Kai Leung (容啟亮)** (“**Prof. Yung**”), aged 73, is an independent non-executive Director of the Company. Also, he is a member of each of the audit committee, the Nomination Committee and the Remuneration Committee of the Company. He joined the Group in February 2017 and is responsible for participating in meetings of the Board to bring an independent perspective and judgment on issues of strategy, performance, accountability, resources, key appointments and standards of conduct and transactions which are material to the Group as and when required.

Prof. Yung graduated from Brighton University, the United Kingdom with a bachelor’s degree in electronic engineering in 1975. He further obtained a master’s degree in automatic control systems from Imperial College of Science, Technology and Medicine, London, the United Kingdom in 1976 and his doctorate in microprocessor applications in process control from the Plymouth University, the United Kingdom in 1985. He is a fellow member of the Hong Kong Institute of Engineers and a fellow of the Hong Kong Academy of Engineering Sciences. In 2015, Prof. Yung was awarded the Bronze Bauhinia Star for his contributions to scientific research.

Since 1986, Prof. Yung held various positions at The Hong Kong Polytechnic University. He is currently the Chair Professor of Precision Engineering and Associate Head in the Department of Industrial and Systems Engineering at The Hong Kong Polytechnic University. He has been appointed as Sir Sze-yuen Chung Professor in Precision Engineering with effect from 1 March 2020.

Prof. Yung has entered into a service agreement with the Company for an initial fixed term of three years commencing from 1 February 2017. The service agreement may be terminated in accordance with the respective terms of the service agreement. Prof. Yung is entitled to receive a total service fee of HK\$22,000 as an independent non-executive Director and a member of the respective Board committees per month.

As at the Latest Practicable Date, Prof. Yung is not interested in any securities issued by the Company or any of its associated corporations within the meaning of Part XV of the SFO.

As at the Latest Practicable Date and save as disclosed herein, none of the above Directors (i) held any directorships in other listed public companies in Hong Kong or overseas in the last three years, or any other major appointments or professional qualifications; (ii) held any other positions with the Company and its subsidiaries; and (iii) had any other relationship with any Directors, senior management, substantial or Controlling Shareholders of the Company.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules nor any other matters that need to be brought to the attention of the Shareholders in relation to the re-election of the above Directors.

\* For identification purpose only.

---

## NOTICE OF AGM

---



**NOTICE IS HEREBY GIVEN THAT** the annual general meeting (the “**Meeting**”) of Vincent Medical Holdings Limited (the “**Company**”) will be held at 17th Floor, Leighton, 77 Leighton Road, Causeway Bay, Hong Kong on Thursday, 18 May 2023 at 10:00 a.m. for the following purposes:

### **AS ORDINARY RESOLUTIONS**

To consider and if thought fit, pass the following resolutions (with or without modification) as ordinary resolutions of the Company:

1. To receive, consider and adopt the audited consolidated financial statements of the Company and the reports of the directors (the “**Directors**”) and the auditor of the Company (the “**Auditor**”) for the year ended 31 December 2022.
2. To re-elect Mr. Choi Man Shing as an executive Director.
3. To re-elect Mr. Choi Cheung Tai Raymond as an executive Director.
4. To re-elect Prof. Yung Kai Leung as an independent non-executive Director.
5. To authorise the board of the Directors to fix the remuneration of the Directors.
6. To re-appoint RSM Hong Kong as the Auditor and authorise the board of the Directors to fix their remuneration.

---

## NOTICE OF AGM

---

7. To consider and if thought fit, pass the following resolution (with or without modification) as an ordinary resolution of the Company:

**“THAT:**

- (a) subject to paragraph (c) below, the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company to allot, issue, and deal with the unissued shares in the share capital of the Company (the “**Shares**”) be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) above shall be in addition to any other authorisation given to the Directors and shall authorise the Directors during the Relevant Period (as hereinafter defined) to make or grant offers, agreements and/or options which may require the exercise of such power during or after the end of the Relevant Period;
- (c) the total number of Shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to options or otherwise) by the Directors during the Relevant Period pursuant to paragraph (a) above, otherwise than pursuant to (i) a Rights Issue (as hereinafter defined); or (ii) any scrip dividend or similar arrangement providing for the allotment and issue of Shares in lieu of the whole or part of a dividend on Shares in accordance with the articles of association of the Company (the “**Articles**”) in force from time to time; or (iii) any specific authority granted by the shareholders of the Company (the “**Shareholders**”) in general meeting(s); or (iv) any issue of Shares upon the exercise of rights of subscription or conversion under the terms of any existing convertible notes issued by the Company or any existing securities of the Company which carry rights to subscribe for or are convertible into Shares, shall not exceed 20% of the total number of issued Shares as at the date of the passing of this resolution, and the said approval shall be limited accordingly;
- (d) if, after the passing of this resolution, the Company conducts a share consolidation or subdivision, the number of Shares subject to the limit set out in paragraph (c) above shall be adjusted to the effect that the number of Shares subject to the limit set out in paragraph (c) above as a percentage of the total number of issued Shares at the time immediately before and after such consolidation or subdivision shall be the same; and

---

## NOTICE OF AGM

---

- (e) for the purpose of this resolution:

“**Relevant Period**” means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by any applicable law or the Articles to be held; and
- (iii) the revocation, variation or renewal of the authority given under this resolution by an ordinary resolution of the Shareholders in general meeting;

“**Rights Issue**” means an offer of Shares, or offer or issue of warrants, options or other securities giving rights to subscribe for Shares open for a period fixed by the Directors to holders of Shares whose names appear on the register of members on a fixed record date in proportion to their holdings of Shares (subject to such exclusion or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or, having regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the exercise or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, any recognised regulatory body or any stock exchange applicable to the Company).”

8. To consider and if thought fit, pass the following resolution (with or without modification) as an ordinary resolution of the Company:

“**THAT:**

- (a) subject to paragraph (c) below, the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company to repurchase issued Shares, subject to and in accordance with all applicable laws and the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as amended from time to time, be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) above shall be in addition to any other authorisation given to the Directors and shall authorise the Directors on behalf of the Company during the Relevant Period (as hereinafter defined) to procure the Company to repurchase Shares at a price determined by the Directors;
- (c) the total number of Shares which are authorised to be repurchased by the Directors pursuant to the approval in paragraph (a) above shall not exceed 10% of the total number of issued Shares as at the date of the passing of this resolution, and the said approval shall be limited accordingly;

---

## NOTICE OF AGM

---

- (d) if, after the passing of this resolution, the Company conducts a share consolidation or subdivision, the number of Shares subject to the limit set out in paragraph (c) above shall be adjusted to the effect that the number of Shares subject to the limit set out in paragraph (c) above as a percentage of the total number of issued Shares at the time immediately before and after such consolidation or subdivision shall be the same; and
- (e) for the purposes of this resolution:

“**Relevant Period**” means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by any applicable law or the Articles to be held; and
- (iii) the revocation, variation or renewal of the authority given under this resolution by an ordinary resolution of the Shareholders in general meeting.”

9. To consider and if thought fit, pass the following resolution (with or without modification) as an ordinary resolution of the Company:

“**THAT** conditional upon the passing of resolutions nos. 7 and 8 above, the general mandate to the Directors pursuant to resolution no. 7 be and is hereby extended by the addition thereto of an amount representing the total number of Shares repurchased by the Company under the authority granted pursuant to the resolution no. 8 (up to 10% of the total number of the issued Shares as at the date of the passing of resolution no. 8).”

By order of the Board  
**Vincent Medical Holdings Limited**  
**Choi Man Shing**  
*Chairman and Executive Director*

21 April 2023

*Registered Office:*  
Cricket Square  
Hutchins Drive  
P.O. Box 2681  
Grand Cayman, KY1-1111  
Cayman Islands

*Headquarters and Principal Place  
of Business in Hong Kong:*  
Units 1604-07A, 16/F.  
Two Harbourfront  
22 Tak Fung Street  
Hung Hom, Kowloon  
Hong Kong

---

## NOTICE OF AGM

---

*Notes:*

- (i) A Shareholder entitled to attend and vote at the Meeting is entitled to appoint another person as his/her/its proxy to attend and vote instead of him/her/it; a proxy need not be a Shareholder.
- (ii) In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the vote(s) of the other joint holder(s) as if he/she/it were solely entitled thereto, and for this purpose, seniority shall be determined by the order in which the names stand in the register in respect of such Share.
- (iii) In order to be valid, a form of proxy must be deposited with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong together with the power of attorney or other authority (if any) under which it is signed (or a certified copy thereof) not less than 48 hours before the time appointed for the holding of the Meeting or any adjournment thereof. The completion and return of the form of proxy shall not preclude the Shareholders from attending and voting in person at the Meeting (or any adjourned meeting thereof) if they so wish and in such event, the form of proxy previously submitted shall be deemed to be revoked.
- (iv) For determining the entitlement to attend and vote at the Meeting to be held on Thursday, 18 May 2023, the register of members of the Company will be closed from Monday, 15 May 2023 to Thursday, 18 May 2023, both days inclusive, during which period no transfer of the Shares will be registered. In order to be eligible to attend and vote at the Meeting, all transfer forms accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Friday, 12 May 2023.
- (v) At the Meeting (or at any adjournment thereof), the chairman will put each of the above resolutions to the vote by way of a poll as required under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The poll results will be published on the website of the Company at [www.vincentmedical.com](http://www.vincentmedical.com) and the website of Hong Kong Exchanges and Clearing Limited at [www.hkexnews.hk](http://www.hkexnews.hk) on 18 May 2023.
- (vi) A circular containing the information regarding, inter alia, the general mandates to issue Shares and repurchase Shares and the re-election of retiring Directors of the Company, will be sent to the Shareholders together with the Company's annual report for the year ended 31 December 2022.
- (vii) If tropical cyclone warning signal no. 8 or above remains hoisted or a black rainstorm warning signal is in force at 9:00 am on the date of the Meeting, the Meeting will be postponed. Shareholders may visit the website of the Company at [www.vincentmedical.com](http://www.vincentmedical.com) and the website of Hong Kong Exchanges and Clearing Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for details of the postponement and alternative meeting arrangements.

The Meeting will be held as scheduled when an amber or red rainstorm warning signal is in force.

Shareholders should make their own decision as to whether they would attend the Meeting under bad weather conditions bearing in mind their own situations and if they should choose to do so, they are advised to exercise care and caution.

- (viii) In the event of any inconsistency, the English version of this notice shall prevail over the Chinese version.